Sarepta Therapeutics Inc (SRPT)
121.50
-1.87
(-1.52%)
USD |
NASDAQ |
Dec 27, 16:00
121.62
+0.12
(+0.10%)
After-Hours: 20:00
Sarepta Therapeutics Research and Development Expense (Quarterly): 224.48M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals Inc | 135.83M |
| Alnylam Pharmaceuticals Inc | 270.93M |
| Eli Lilly and Co | 2.734B |
| Catalyst Pharmaceuticals Inc | 3.284M |
| Vertex Pharmaceuticals Inc | 875.90M |